EMA.
Japanese vocalist of the group DUSTCELL
- Reports this week
- 0
- Active events
- 1
- Connections
- 71
What's happening
One to three months ago
-
EMA provided updates to businesses in New Zealand on January 1, 2026.Some support1 report
-
A technical analysis suggests a strong uptrend for the market, driven by RSI showing positive reversal from weakness and a decisive move above EMA.Some support2 reports
-
Homeland Security attached moniker to EMA, while Bush established NIMS through Homeland Security offices across Ohio.Some support1 report
Gone quiet
No new reports in 90+ days-
EMA has been appointed as the director in Pulaski County.Some support1 report
-
TenX plans to consult both the FDA and EMA regarding the results of its clinical trials.Some support1 report
-
Eli Lilly and Company is seeking a positive opinion from the EMA regarding the potential indication expansion for its drug, pirtobrutinib.Some support3 reports
-
A studio located in East Providence, Rhode Island, meets EMA green seal standards, while Rosa ultimately chose the location over opportunities in Los Angeles.Some support1 report
-
The EMA gave a positive opinion for the drug TRYNGOLZA, developed by Ionis Pharmaceuticals, marking a step toward European Commission approval.Some support2 reports
-
EMA granted Orphan Drug Designation to KRRO-110, a drug candidate from Korro Bio, Inc.Some support2 reports
-
Anavex Life Sciences Corp is exploring commercialization efforts in Europe and seeking review for blarcamesine approval from the European Medicines Agency.Some support1 report
-
FDA and EMA granted Rare Pediatric Disease and Orphan Drug Designations to Quoin Pharmaceuticals Ltd.Some support1 report
-
Certara developed and utilized the Simcyp Simulator platform, which the EMA qualified for regulatory submissions, marking a successful collaboration.Some support1 report
-
FDA approved GAMMAGARD LIQUID ERC for use, while EMA had already approved it as DEQSIGA. The company also benefited from market trends.Some support2 reports
-
Sanofi received orphan designation from the European Medicines Agency (EMA).Well supported3 reports
-
Zevra Therapeutics submitted a Marketing Authorization Application to the European Medicines Agency for Arimoclomol, targeting Niemann-Pick Disease Type C.Some support4 reports
-
KalVista Pharmaceuticals received prior regulatory approvals in the UK and the US, and the EMA adopted a positive opinion for its drug sebetralstat, with the EC expected to make a final decision.Some support3 reports1 development inside
-
Bristol Myers Squibb plans to discuss marketing applications with both the FDA and EMA.Well supported3 reports
-
The EMA issued a negative opinion on July 25, 2025, recommending the rejection of Sarepta's Elevidys application for European clearance.Some support2 reports
-
Rhythm plans Phase III trial design discussions with the FDA and EMA and in-licensed bivamelagon from LG Chem.Some support2 reports
-
EMA review led to CE mark certification for FemBloc® on June 25, 2025.Speculative1 report
-
FDA approved Ogsiveo and Mirdametinib, while EMA recommended approval for Ogsiveo, for Merck KGaA.Speculative1 report
-
GeoVax, led by CEO David Dodd, received SA from EMA for its GEO-MVA and presented at a conference in New York City on September 3, 2025.Some support9 reports
-
The FDA and EMA are jointly pushing for the adoption and use of alternative testing assays.Well supported3 reports
No events began in the chosen period. Widen it, or reset.
Around EMA this week
News at the entities that move EMA most-
FDA OperationalDEA guidance restricts state-licensed supply chains in Pennsylvania, relating to FDA-approved products.Moves EMA
-
Eli Lilly and Company OperationalEli Lilly is building a new manufacturing facility in Lehigh Valley, Pennsylvania, while Cisco reports on its market performance.Moves EMA
-
High-profile political and corporate events link DHS, White House, and figures like Trump, Mullin, and Patel.
Moves EMA
-
Europe StructuralEurope withdraws gas reserves during the heating season, coinciding with the discovery of undeclared goods in a vehicle arriving from Germany.Moves EMA
-
European Commission StructuralAndy Burnham will hold talks with the European Commission and Council regarding a trade deal expected to boost GDP and ease food and youth mobility.Moves EMA
-
Philippines Shared contextThe Bureau of Internal Revenue leads tax administration in the Philippines.Moves EMA
Connections
The 16 strongest of 71, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Operational
The agencies actively coordinate regulatory functions, sharing guidance, and influencing each other's drug approval processes.
-
Europe Structural
EMA functions as a key regulatory body within the European system, issuing approvals and opinions for clearance.
-
European Commission Structural
EMA provides required scientific opinions and recommendations that the European Commission must consider for final approval.
-
GeoVax Structural
EMA provides regulatory guidance and scientific advice that influences GeoVax's product development and approval path.
-
Cytokinetics Structural
Cytokinetics is actively seeking marketing authorization from the EMA.
-
Eli Lilly and Company Operational
EMA actively monitors and provides regulatory opinions on Eli Lilly's drug development and products.
-
The individual EMA holds a functional role defined by a specific moniker used by the United States Department of Homeland Security.
-
Fayette County Shared context
EMA officials have issued travel warnings regarding Fayette County.
Show all 16 connections
-
TenX Structural
The company plans to consult EMA regarding the outcomes of its clinical trials.
-
Emirates News Agency Mentioned together
EMA's statements are reported by Emirates News Agency.
-
Port of Manzanillo Operational
EMA's regulatory approval processes relate to the Port of Manzanillo's capacity for handling large container vessels.
-
Pulaski County Shared context
EMA serves as a director within the jurisdiction of Pulaski County.
-
East Providence Shared context
EMA's professional studio operates in East Providence, meeting specific EMA green seal standards.
-
ALPS Structural
ALPS's operations are constrained by guidelines recommended by EMA.
-
Philippines Shared context
An entity associated with EMA is located in the Philippines.
-
George W. Bush Mentioned together
No evidence was provided linking EMA and George W. Bush.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
2 eventsSeptember 2026
1 eventShow 2 earlier months
August 2026
2 eventsJune 2026
18 events- Eli Lilly and Company is seeking a positive opinion from the EMA regarding the potential indication expansion for its drug, pirtobrutinib.
- A studio located in East Providence, Rhode Island, meets EMA green seal standards, while Rosa ultimately chose the location over opportunities in Los Angeles.
- The EMA gave a positive opinion for the drug TRYNGOLZA, developed by Ionis Pharmaceuticals, marking a step toward European Commission approval.
- EMA granted Orphan Drug Designation to KRRO-110, a drug candidate from Korro Bio, Inc.
- Anavex Life Sciences Corp is exploring commercialization efforts in Europe and seeking review for blarcamesine approval from the European Medicines Agency.
- FDA and EMA granted Rare Pediatric Disease and Orphan Drug Designations to Quoin Pharmaceuticals Ltd.
- Certara developed and utilized the Simcyp Simulator platform, which the EMA qualified for regulatory submissions, marking a successful collaboration.
- FDA approved GAMMAGARD LIQUID ERC for use, while EMA had already approved it as DEQSIGA. The company also benefited from market trends.
- Sanofi received orphan designation from the European Medicines Agency (EMA).
- Zevra Therapeutics submitted a Marketing Authorization Application to the European Medicines Agency for Arimoclomol, targeting Niemann-Pick Disease Type C.
- KalVista Pharmaceuticals received prior regulatory approvals in the UK and the US, and the EMA adopted a positive opinion for its drug sebetralstat, with the EC expected to make a final decision.
- Bristol Myers Squibb plans to discuss marketing applications with both the FDA and EMA.
- The EMA issued a negative opinion on July 25, 2025, recommending the rejection of Sarepta's Elevidys application for European clearance.
- Rhythm plans Phase III trial design discussions with the FDA and EMA and in-licensed bivamelagon from LG Chem.
- EMA review led to CE mark certification for FemBloc® on June 25, 2025.
- FDA approved Ogsiveo and Mirdametinib, while EMA recommended approval for Ogsiveo, for Merck KGaA.
- GeoVax, led by CEO David Dodd, received SA from EMA for its GEO-MVA and presented at a conference in New York City on September 3, 2025.
- The FDA and EMA are jointly pushing for the adoption and use of alternative testing assays.